Regeneron climbs as bone disorder drug succeeds in late-stage trial

** Shares of drugmaker Regeneron Pharmaceuticals REGN.O rise 1.9% to $585.67

** Co says its experimental treatment, garetosmab, significantly reduced abnormal bone formation in patients with fibrodysplasia ossificans progressiva

** FPO is a condition where muscle, tendon and ligament tissues gradually turn into bones, causing progressive loss of mobility and reduced life expectancy

** Co plans to file U.S. marketing application for the drug by the end of 2025, with global regulatory submissions slated for 2026

** Including session's move, stock down 18.4% YTD